Bloomberg report should be good for PRR today imo.
Dendreon Corp. (DNDN US) rose 94 percent to $22.94 for the biggest gain in Russell 2000 Index. The company’s prostate cancer therapy Provenge, the first malignancy-fighting immunotherapy, extended men’s lives by four months in a study. Wachovia Corp. upgraded the stock to “outperform” from “market perform,” saying the results were “impressive.”
